Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cardiovascular/Thrombocytopenia

Thrombocytopenia

81

Pipeline Programs↗

128

Active Trials↗

63

Companies Involved↗

Thrombocytopenia is a moderately active landscape with 81 programs across 63 companies. 15 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

67/100

Mech. Concentration

10/100

Completion Rate

67/100

Attrition Rate

14/100

Pipeline

Programs by Phase

Preclinical29

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Linezolid

Pfizer

Sofosbuvir

Gilead

Fresh Frozen Plasma

CSL Behring

Platelets

Leiden University Medical Center

Phase 15

Rxim002

RiboX Therapeutics Ltd.

Anti-CD19 CAR NK Cells

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

SHR-2173

Guangdong Hengrui Pharmaceutical Co., Ltd

PRG-1801

Tongji Hospital

QT-019C

Tianjin Huanhu Hospital

Phase 232

Baricitinib

Eli Lilly

Ruxolitinib

Incyte

Apixaban

Bristol-Myers Squibb

Selinexor

Karyopharm Therapeutics Inc

Herombopag

Jiangsu HengRui Medicine Co., Ltd.

Phase 315

Hetrombopag Olamine

Jiangsu HengRui Medicine Co., Ltd.

Pacritinib

Sobi, Inc.

Rhtpo

Shandong University

Hetrombopag

Jiangsu HengRui Medicine Co., Ltd.

Efgartigimod

Argenx

Approved

No programs

Analysis

Modality Breakdown

86%

Small molecule

61 of 71 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 71 classified programs, each share of the total. Modality classified for 95% of 81 pipeline programs.

Analysis

Trial Status

359

clinical trials

Completed106 · 30%

Recruiting78 · 22%

Unknown status72 · 20%

Not yet recruiting33 · 9%

Terminated32 · 9%

Withdrawn20 · 6%

Other18 · 5%

Clinical Trials

Trial Activity

359 trials

A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)

Recruiting· Novartis logo

Novartis·Phase 2·NCT07421167·164 enrolled

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP).

Recruiting· Amgen logo

Amgen·Phase 3·NCT07700238·126 enrolled

Safety and Efficacy of Baricitinib in Thrombopoietin-Receptor-Agonist-Refractory Persistent Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation: A Phase Ib/II Study

Recruiting·PPeking University People's Hospital·Preclinical·NCT07535645·28 enrolled

An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia

Recruiting·NNuvig Therapeutics, Inc.·Phase 2·NCT07095127·30 enrolled

A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Recruiting· Incyte logo

Incyte·Phase 2·NCT07104565·56 enrolled

A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Adult Patients With Chronic Immune Thrombocytopenia (ITP)

Recruiting·—·Phase 3·NCT07059000·40 enrolled

Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Preclinical·NCT06456528·235 enrolled

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Safety and Efficacy of SG301 SC Injection in Patients With Primary Immune Thrombocytopenia

Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 2·NCT07710248·60 enrolled

Efficacy and Safety of Multi-Target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia: A Prospective, Single-arm, Multicenter, Exploratory Trial

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Approved·NCT07788456·38 enrolled

Patients' Preferences for Primary Immune Thrombocytopenia Treatment

Recruiting· Novartis logo

Novartis·N/A·NCT07786077·100 enrolled

Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia

Recruiting·AAnhui Provincial Hospital·Phase 2·NCT06898983·97 enrolled

A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

Recruiting·JJiangsu BioJeTay Biotechnology Co., Ltd.·Preclinical·NCT06929299·56 enrolled

A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP

Recruiting· Argenx logo

Argenx·Preclinical·NCT07194850·24 enrolled

Real-world Treatment Patterns and Outcomes of Eltrombopag in Patients With Primary Immune Thrombocytopenia

Recruiting· Novartis logo

Novartis·N/A·NCT07587723·150 enrolled

A Phase 2 Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab.

Recruiting· Novartis logo

Novartis·Phase 2·NCT07039422·60 enrolled

Page 1 of 24

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)